Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-12-14 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains detailed tables regarding the 'Resulting situation on the date on which threshold was crossed or reached' for voting rights and financial instruments held by JPMorgan Chase & Co. This structure is characteristic of regulatory filings concerning changes in significant share ownership. The presence of 'RNS Number' and the footer mentioning RNS (news service of the London Stock Exchange) confirms it is a regulatory announcement. The specific content aligns perfectly with the definition of a Major Shareholding Notification (crossing ownership thresholds).
2023-12-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document explicitly starts with 'RNS Number : 8246W' and contains detailed tables regarding 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the core content is a specific regulatory filing about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2023-12-14 English
Rule 2.9 Announcement
Major Shareholding Notification Classification · 99% confidence The document is identified by the RNS Number (7045W) and the header 'Dechra Pharmaceuticals PLC' dated '13 December 2023'. The content explicitly states it is a 'Rule 2.9 Announcement' under the 'City Code on Takeovers and Mergers (the "Code")'. Rule 2.9 requires the company to announce the total number of shares in issue and ISIN when a takeover offer is made or when a Rule 2.4 announcement is made. This is a specific regulatory disclosure related to a potential takeover/merger activity, but it is not the M&A announcement itself (TAR) nor a general regulatory filing (RNS). Since it deals with the mechanics and disclosure requirements surrounding a potential takeover bid under the Takeover Code, it is most closely related to M&A Activity (TAR) or, given its nature as a mandatory disclosure under specific takeover rules, it could be considered a specialized regulatory filing. However, the core subject matter is the share capital count in the context of a takeover. Given the options, 'TAR' (M&A Activity) is the most relevant category for disclosures mandated by the Takeover Code regarding share structure during an offer period. If TAR is too specific for a Rule 2.9 update, 'RNS' (Regulatory Filings) is the fallback. Since the document is a formal, mandatory announcement under the Takeover Code, and the context is clearly related to a potential takeover (implied by the reference to the Code and the detailed disclosure rules 8.3), TAR is the best fit, although RNS is also plausible if TAR is reserved only for the initial bid announcement. Given the specific nature of the disclosure (Rule 2.9), I will classify it as a specialized regulatory filing, RNS, as it is a mandatory disclosure notification rather than the primary M&A announcement itself.
2023-12-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is identified by the 'RNS Number' and contains the header 'TR-1: Standard form for notification of major holdings'. This specific form (TR-1) is used in the UK/EU regulatory framework (under DTR 5) to report changes in major shareholdings (insider transactions or significant investor changes). This directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it is distributed via RNS, the content itself is a specific regulatory disclosure about share ownership thresholds being crossed, making MRQ the most precise classification over the general RNS fallback.
2023-12-13 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure/Dealing Disclosure made by a person with interests representing 1% or more in relevant securities during a takeover situation. This type of filing relates to insider/significant shareholder activity during a takeover bid, which falls under the scope of M&A activity or significant shareholding notification, but the specific context of a Takeover Code disclosure strongly suggests a connection to a takeover or merger proposal. Reviewing the definitions: - TAR (M&A Activity): Announcements and documents related to merger proposals or takeover bids. - MRQ (Major Shareholding Notification): Notification of changes in significant share ownership levels (crossing thresholds). Since this is a mandatory disclosure under the Takeover Code (Rule 8.3) related to interests in securities during an offer, it is most accurately classified as related to M&A Activity (TAR), as it is a direct consequence of a takeover/merger situation involving Dechra Pharmaceuticals plc. If TAR was not available, MRQ might be considered, but TAR is more specific to the context provided by the 'Takeover Code' reference.
2023-12-13 English
Dechra Pharmaceuticlas PLC - Resolutions passed
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESOLUTIONS' and details the specific resolutions passed at the Annual General Meeting (AGM) of Dechra Pharmaceuticals PLC on December 13, 2023. It outlines ordinary and special resolutions regarding share allotment, pre-emption rights, and market purchases of shares. Since these are the formal results of the voting process at an AGM, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2023-12-13 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.